Media
Patient Recruitment Advertisement
The following clinical study, jointly sponsored by Angel Pharmaceuticals (Jiaxing Angel Pharmaceuticals Co., Ltd.) and Corvus Pharmaceuticals, is currently being conducted in China: "A Phase I/Ib Dose-Escalation Trial Evaluating the Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor CPI-818 in Subjects with Relapsed/Refractory T-Cell Lymphomas." This study has received drug clinical trial authorization from the National Medical Products Administration (NMPA) of China (Approval Nos.: 2021LP01648/2021LP01646) and has been approved by the Ethics Committees of the participating clinical study sites.
The investigational drug in this study is designated CPI-818 and is provided by the sponsor, Corvus Pharmaceuticals. CPI-818 is a first-in-class oral investigational drug that works by inhibiting interleukin (IL)-2-inducible T-cell kinase (ITK). ITK is a critical component of the signal transduction pathway in T-cell lymphomas, and CPI-818 can block the rapid proliferation of cancerous T cells by inhibiting this pathway. This study is designed to evaluate the safety and tolerability of the investigational drug CPI-818 in patients with relapsed/refractory T-cell lymphomas.
Patients enrolled in the study will receive standardized treatment and will be followed up throughout the entire process by a professional and dedicated medical team on a regular, scheduled, and professional basis. In addition to providing professional treatment, the team will promptly detect any changes in the patient's condition and potential treatment-related adverse reactions, and provide timely further treatment recommendations and plans. Regular follow-up visits during the study period will enable early detection of disease progression.
If you meet the following enrollment criteria:
1. Age ≥ 18 years;
2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
3. Histologically confirmed T-cell lymphoma (previous pathological examination results are acceptable); disease progression, refractory, relapsed, or intolerance after receiving at least 2 standard therapies for advanced or recurrent disease, or as determined by the physician that no more than 1 established therapy exists for the disease;
4. Able to provide an archived tumor tissue sample within 90 days prior to the first dose or undergo a tumor tissue biopsy;
5. Able to adhere to scheduled follow-up visits, communicate well with the investigator, and comply with study requirements.
If you are interested in this study, you may consult through the following channels for more details.
**Contact Us**
**Currently Activated Study Sites:**
**Peking University Cancer Hospital**
Principal Investigator: Song Yuqin
Department: Department of Lymphoma
Location: Beijing
Contact Person: Teacher Du
Contact Number: 17643034121
**Shanghai East Hospital**
Principal Investigator: Guo Ye
Department: Department of Oncology
Location: Shanghai
Contact Person: Teacher Fu
Contact Number: 13918590742
**Beijing Friendship Hospital, Capital Medical University**
Principal Investigator: Wang Zhao
Department: Department of Hematology
Location: Beijing
Contact Person 1: Teacher Zhang
Contact Number 1: 18810124452
Contact Person 2: Teacher Su
Contact Number 2: 18515093040
**Henan Cancer Hospital**
Principal Investigator: Liu Yanyan
Department: Department of Lymphoma Comprehensive Internal Medicine
Location: Zhengzhou
Contact Person: Teacher Guo
Contact Number: 18603818049
**Beijing Boren Hospital**
Principal Investigator: Hu Kai
Department: Department of Hematology (Fourth Division)
Location: Beijing
Contact Person 1: Teacher Cheng
Contact Number 1: 13241828010 (same as WeChat)
Contact Person 2: Teacher Huang
Contact Number 2: 18511306571
**Note:** A total of 20 centers nationwide are being gradually activated.
